Meeting
2014 ASCO Annual Meeting
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).
Authors
Vassiliki Papadimitrakopoulou
The University of Texas MD Anderson Cancer Center, Houston, TX
Vassiliki Papadimitrakopoulou , J. Jack Lee , Ignacio Ivan Wistuba , Anne S. Tsao , Frank V. Fossella , John Heymach , Neda Kalhor , Sanjay Gupta , Scott N. Gettinger , Lauren Averett Byers , Julie Izzo , Vincent A. Miller , Lixia Diao , Jing Wang , Caimiao Wei , Kevin R. Coombes , David J. Mauro , Eric H. Rubin , Waun Ki Hong , Roy S. Herbst
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01248247
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8042)
DOI
10.1200/jco.2014.32.15_suppl.8042
Abstract #
8042
Poster Bd #
223
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).
First Author: Vassiliki Papadimitrakopoulou
Poster
2013 ASCO Annual Meeting
Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.
First Author: Giuseppe Giaccone
Poster
2016 ASCO Annual Meeting
Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.
First Author: Matthias Scheffler
Poster
2015 ASCO Annual Meeting
Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC.
First Author: Lanying Gou Jr.